TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18786316

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Multiple daily insulin injection (MDI)
Number of subjects: 94
Study: 16575844

Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment (ACT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Integrated Treatment (IT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Treatment
Number of subjects: 0
Study: 11834107

Group type: EXPERIMENTAL
Intervention: Zone diet
Number of subjects: 8
Study: 9869772

Group type: EXPERIMENTAL
Intervention: Cryopreserved platelets
Number of subjects: 73

Group type: COMPARATOR
Intervention: Liquid-preserved platelets
Number of subjects: 73
Study: 8676535

Group type: EXPERIMENTAL
Intervention: 6-hour enteral nutrition (EN) at 2 kcal/min for 6 hours
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 12-hour enteral nutrition (EN) at 1 kcal/min for 12 hours
Number of subjects: 6

Group type: COMPARATOR
Intervention: Oral meal
Number of subjects: 6
Study: 1611137

Group type: EXPERIMENTAL
Intervention: ponalrestat 600 mg per day
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 6436633

Group type: EXPERIMENTAL
Intervention: Wheelchair exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: Arm cranking exercise
Number of subjects: 10
Study: 31116891

Group type: EXPERIMENTAL
Intervention: Subcutaneous oxytocin (4 µg/4 ml saline)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Subcutaneous lidocaine 1% (4 ml)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study: 29740733

Group type: EXPERIMENTAL
Intervention: Experimental voucher condition (residential mobility out of public housing into lower poverty neighborhoods)
Number of subjects: 2829

Group type: COMPARATOR
Intervention: Control group (remaining in public housing)
Number of subjects: 2829

Group type: EXPERIMENTAL
Intervention: Experimental voucher condition
Number of subjects: 2829
Study: 26265099

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HDMTX) treatment
Number of subjects: 30
Study: 24865255

Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (ATG) during induction phase of immunosuppression (IPI)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard induction therapy
Number of subjects: 49
Study: 22959283

Group type: EXPERIMENTAL
Intervention: Donepezil + Choline Alphoscerate
Number of subjects: 91

Group type: COMPARATOR
Intervention: Donepezil + Placebo
Number of subjects: 91
Study: 20456026

Group type: EXPERIMENTAL
Intervention: Packable composite (Filtek P60)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Packable composite (Filtek P60) with flowable composite (Filtek Z350) as liner
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (Packable composite alone)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Water storage and thermocycling
Number of subjects: 80
Study: 17655773

Group type: EXPERIMENTAL
Intervention: Electronic Voting System (EVS)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Traditional teaching
Number of subjects: 127
Study: 16088180

Group type: EXPERIMENTAL
Intervention: Dye-enhanced laser ablation (DLA) using a low-power diode laser at 10 W with ICG concentration of 0.5 mg/ml.
Number of subjects: 37

Group type: COMPARATOR
Intervention: Cavitron ultrasonic surgical aspirator (CUSA)
Number of subjects: 37
Study: 12391535

Group type: EXPERIMENTAL
Intervention: Desflurane anaesthesia supplemented by 2 mg tropisetron
Number of subjects: 150

Group type: COMPARATOR
Intervention: Propofol total intravenous anaesthesia (TIVA)
Number of subjects: 150
Study: 10423055

Group type: EXPERIMENTAL
Intervention: Twice-daily morphine sulphate controlled-release suppositories
Number of subjects: 6

Group type: COMPARATOR
Intervention: Once-daily morphine sulphate controlled-release suppositories
Number of subjects: 6
Study: 7582383

Group type: EXPERIMENTAL
Intervention: Oral methylergometrine (0.125 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous methylergometrine (0.200 mg)
Number of subjects: 12
Study: 1648886

Group type: EXPERIMENTAL
Intervention: Ofloxacin administration
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 12
Study: 6138084

Group type: EXPERIMENTAL
Intervention: 15 mg midazolam
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 15 mg oxazepam
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30968123

Group type: EXPERIMENTAL
Intervention: Lipid-based, ready-to-use supplementary food (RUSF)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Special corn-soy blend 'plus plus' (CSB++)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Locally processed, fortified flour (MI)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Locally milled flours plus oil, sugar, and micronutrient powder (LMF)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Recovery status
Number of subjects: 286
Study: 28722167

Group type: EXPERIMENTAL
Intervention: Assisted autogenic drainage (AAD) with standard nursing care
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standard nursing care
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Assisted autogenic drainage (AAD)
Number of subjects: 29
Study: 26884049

Group type: EXPERIMENTAL
Intervention: self-guided internet-based stress management intervention (iSMI)
Number of subjects: 264

Group type: COMPARATOR
Intervention: wait-list control group (WLC)
Number of subjects: 264
Study: 24563519

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (combined selenium only and selenium + vitamin E arms)
Number of subjects: 3117

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (alone)
Number of subjects: 3117

Group type: COMPARATOR
Intervention: No supplementation (baseline selenium status)
Number of subjects: 3117
Study: 21760499

Group type: EXPERIMENTAL
Intervention: Acetaminophen ER 1300 mg
Number of subjects: 610

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 610
Study: 19250753

Group type: EXPERIMENTAL
Intervention: Partner reflection condition
Number of subjects: 29

Group type: COMPARATOR
Intervention: Cross-sex friend reflection condition
Number of subjects: 29
Study: 17723128

Group type: EXPERIMENTAL
Intervention: Foot exercises against increased resistance
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sitting motionless with feet not touching the floor
Number of subjects: 21

Group type: COMPARATOR
Intervention: Immobility of seated subjects
Number of subjects: 21

Group type: COMPARATOR
Intervention: Airline-recommended activities and foot exercises
Number of subjects: 21

Group type: COMPARATOR
Intervention: Foot exercises against moderate resistance
Number of subjects: 21
Study: 16022852

Group type: EXPERIMENTAL
Intervention: 150 mg of DMPA from a multidose vial (400 mg/mL)
Number of subjects: 95

Group type: COMPARATOR
Intervention: 150 mg of DMPA from a single-unit-dose vial (150 mg/mL)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Multidose group
Number of subjects: 95

Group type: COMPARATOR
Intervention: Unit-dose group
Number of subjects: 95
Study: 12221311

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (culturally sensitive group program in addition to individual supportive therapy)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Individual supportive therapy (control group)
Number of subjects: 48
Study: 9697820

Group type: EXPERIMENTAL
Intervention: Fluvastatin (40 mg twice daily)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Fluvastatin (40 mg twice daily) with L‐NMMA (4 micromol/min)
Number of subjects: 29
Study: 8590530

Group type: EXPERIMENTAL
Intervention: Simvastatin (10-40 mg/day)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Fibrate therapy (gemfibrozil 900 mg/day, ciprofibrate 100 mg/day, bezafibrate 400 mg/day, fenofibrate 300 or 400 mg/day)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 800

Group type: COMPARATOR
Intervention: Fibrate therapy
Number of subjects: 800
Study: 1699814

Group type: EXPERIMENTAL
Intervention: Iloprost
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 394300

Group type: EXPERIMENTAL
Intervention: Atropine (0.6 mg) and meperidine (1 mg/kg body weight)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (benzocaine and intravenous diazepam only)
Number of subjects: 100
Study: 31108564

Group type: EXPERIMENTAL
Intervention: Prescribing recommendations generated by a physician using STRIP Assistant
Number of subjects: 124

Group type: COMPARATOR
Intervention: Usual care medication review (Control)
Number of subjects: 124
Study: 28771379

Group type: EXPERIMENTAL
Intervention: VR plus standard treatment group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard treatment (ST) group
Number of subjects: 50
Study: 26461465

Group type: EXPERIMENTAL
Intervention: One-stage full-mouth disinfection (FMD)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Scaling and root planing per quadrant (SRP-Q)
Number of subjects: 78
Study: 23386261

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir plus abacavir/lamivudine
Number of subjects: 95

Group type: COMPARATOR
Intervention: lopinavir/ritonavir monotherapy
Number of subjects: 95
Study: 22260837

Group type: EXPERIMENTAL
Intervention: 3d triple therapy (rabeprazole 10mg + furazolidone 100mg + clarithromycin 250mg for 3 days)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: 5d triple therapy (rabeprazole 10mg + furazolidone 100mg + clarithromycin 250mg for 5 days)
Number of subjects: 116

Group type: COMPARATOR
Intervention: 7d triple therapy (rabeprazole 10mg + furazolidone 100mg + clarithromycin 250mg for 7 days)
Number of subjects: 116
Study: 19711845

Group type: EXPERIMENTAL
Intervention: Viferon (suppositories of human recombinant interferon alfa‐2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Arbidol (reference drug)
Number of subjects: 0
Study: 17557257

Group type: EXPERIMENTAL
Intervention: Economic evaluations of health interventions in nephrology
Number of subjects: 0
Study: 15465451

Group type: EXPERIMENTAL
Intervention: Dual-task condition (visuomotor tracking task + somatosensory oddball task)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oddball-only condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual-task condition with unpredictable tracking direction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual-task condition with fastest tracking speed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual-task condition with predictable tracking direction
Number of subjects: 0
Study: 11219471

Group type: EXPERIMENTAL
Intervention: Telmisartan (40 mg titrated to 80 mg titrated to 120 mg)
Number of subjects: 533

Group type: COMPARATOR
Intervention: Atenolol (50 mg titrated to 100 mg)
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 533

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 533
Study: 9482510

Group type: EXPERIMENTAL
Intervention: Buflomedil 400 mg intravenous daily for 5 days
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 39
Study: 8037262

Group type: EXPERIMENTAL
Intervention: Hallucinated 'voices'
Number of subjects: 4

Group type: COMPARATOR
Intervention: Comparison speakers
Number of subjects: 4
Study: 3132275

Group type: EXPERIMENTAL
Intervention: Atropine (30 micrograms/kg intravenous)
Number of subjects: 10
Study: 4895338

Group type: EXPERIMENTAL
Intervention: Methoxyflurane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nitrous oxide
Number of subjects: 0
Study: 31550290

Group type: EXPERIMENTAL
Intervention: Verbal suggestion indicating less painful stimuli (green or red colour)
Number of subjects: 56

Group type: COMPARATOR
Intervention: No verbal suggestion (control group)
Number of subjects: 56
Study: 29197414

Group type: EXPERIMENTAL
Intervention: IBBIS mental health care integrated with IBBIS vocational rehabilitation
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: IBBIS mental health care and standard vocational rehabilitation
Number of subjects: 603

Group type: COMPARATOR
Intervention: Standard mental health care and standard vocational rehabilitation
Number of subjects: 603
Study: 26377553

Group type: EXPERIMENTAL
Intervention: Physical activity in daily living
Number of subjects: 74
Study: 23929355

Group type: EXPERIMENTAL
Intervention: multifaceted intervention: team‐based supported employment, systematic medication management, and other behavioral health services
Number of subjects: 2059

Group type: COMPARATOR
Intervention: usual services (control group)
Number of subjects: 2059

Group type: EXPERIMENTAL
Intervention: multifaceted intervention
Number of subjects: 2059
Study: 20807305

Group type: EXPERIMENTAL
Intervention: Short compression with QuikClot® Interventional™ pad (15 minutes, group 1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Short compression (15 minutes, group 2)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional prolonged compression (2 hours, group 3)
Number of subjects: 120
Study: 18328608

Group type: EXPERIMENTAL
Intervention: Korsakoff patients with additional processing and response time, additional explanation, and explicit encouragement
Number of subjects: 2

Group type: COMPARATOR
Intervention: Korsakoff patients without additional support
Number of subjects: 2

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 2
Study: 16490581

Group type: EXPERIMENTAL
Intervention: FSC 220/42 microg HFA (2 inhalations of FSC 110/21 microg)
Number of subjects: 365

Group type: COMPARATOR
Intervention: FP 220 microg CFC (2 inhalations of FP 110 microg)
Number of subjects: 365

Group type: COMPARATOR
Intervention: SAL 42 microg CFC (2 inhalations of 21 microg)
Number of subjects: 365

Group type: COMPARATOR
Intervention: PLA HFA (2 inhalations of PLA)
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: FSC
Number of subjects: 365

Group type: COMPARATOR
Intervention: FP
Number of subjects: 365

Group type: COMPARATOR
Intervention: SAL
Number of subjects: 365

Group type: COMPARATOR
Intervention: PLA
Number of subjects: 365
Study: 12641499

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 10769552

Group type: EXPERIMENTAL
Intervention: 20 ppm inhaled nitric oxide
Number of subjects: 15

Group type: COMPARATOR
Intervention: 5 ppm inhaled nitric oxide
Number of subjects: 15
Study: 9745813

Group type: EXPERIMENTAL
Intervention: Systemic steroid therapy
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Systemic antibiotic therapy
Number of subjects: 41
Study: 8452185

Group type: EXPERIMENTAL
Intervention: 400 mg of fleroxacin orally
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 100 mg of fleroxacin intravenously
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Dose adjustment recommended for patients with renal disease (GFR < 40 mL/min)
Number of subjects: 2
Study: 3524668

Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 150

Group type: COMPARATOR
Intervention: TENS placebo
Number of subjects: 150
Study: 27382968

Group type: EXPERIMENTAL
Intervention: Mental Agility and Psychological Strength training (4-hour resilience training intervention)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Training as Usual (TAU)
Number of subjects: 45
Study: 24676365

Group type: EXPERIMENTAL
Intervention: Apple
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Spinach
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Apple + Spinach
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study: 22715865

Group type: EXPERIMENTAL
Intervention: ACAT-initiated pharmacist home medicines review (APHMR)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Pharmacist review of ACAT files
Number of subjects: 80

Group type: COMPARATOR
Intervention: ACAT usual care
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Feedback from GPs on pharmacist medication reviews
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Patient feedback on pharmacist home visits
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ACAT clinician feedback on pharmacist-led medication review
Number of subjects: 80
Study: 20185746

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 2685

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 2685

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2685
Study: 18705531

Group type: EXPERIMENTAL
Intervention: Val/HCTZ 320/25 mg
Number of subjects: 2702

Group type: EXPERIMENTAL
Intervention: Val/HCTZ 320/12.5 mg
Number of subjects: 2702

Group type: COMPARATOR
Intervention: Val 320 mg
Number of subjects: 2702
Study: 16581420

Group type: EXPERIMENTAL
Intervention: SA60AT single‐piece IOL
Number of subjects: 40

Group type: COMPARATOR
Intervention: MA60AC 3‐piece IOL
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both SA60AT and MA60AC
Number of subjects: 40
Study: 12518369

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (L-AmB) 3 mg/kg intravenously 3 times per week
Number of subjects: 139

Group type: COMPARATOR
Intervention: Combination of fluconazole (200 mg orally every 12 hours) and itraconazole (200 mg orally every 12 hours)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: L-AmB
Number of subjects: 139

Group type: COMPARATOR
Intervention: F+I
Number of subjects: 139
Study: 10685588

Group type: EXPERIMENTAL
Intervention: Head-down bed rest (HDBR)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Post-HDBR supine position
Number of subjects: 6

Group type: COMPARATOR
Intervention: Head-up tilt (HUT) test before HDBR
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Head-up tilt (HUT) test after HDBR
Number of subjects: 6
Study: 9337600

Group type: EXPERIMENTAL
Intervention: self‐exposure and cognitive restructuring
Number of subjects: 20

Group type: COMPARATOR
Intervention: progressive relaxation training
Number of subjects: 20
Study: 1437427

Group type: EXPERIMENTAL
Intervention: Personalized letter reminder about the need for an influenza vaccination
Number of subjects: 124

Group type: COMPARATOR
Intervention: No reminder
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Personalized letter reminder
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Parental worry about asthma
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Parental worry about vaccine side effects
Number of subjects: 124
Study: 3839558

Group type: EXPERIMENTAL
Intervention: Group I (arthrotomy and medial meniscectomy)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Group II (extraarticular substitution of the anterior cruciate ligament)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 35
Study: 31175716

Group type: EXPERIMENTAL
Intervention: Steam inhalation at 42-44°C
Number of subjects: 0
Study: 31107728

Group type: EXPERIMENTAL
Intervention: More acculturated parents
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Parents who perceive their child as having a weight problem
Number of subjects: 117
Study: 29215806

Group type: EXPERIMENTAL
Intervention: LCD-based visual field testing system (LVF)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Standard automated perimetry (HFA)
Number of subjects: 330
Study: 26135774

Group type: EXPERIMENTAL
Intervention: nsNIPPV
Number of subjects: 63

Group type: COMPARATOR
Intervention: NCPAP
Number of subjects: 63
Study: 24354541

Group type: EXPERIMENTAL
Intervention: Open technique (eyelid crease incision operation)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Closed technique (supralash stab incision)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 44
Study: 23127292

Group type: EXPERIMENTAL
Intervention: Endocrine therapy alone
Number of subjects: 1113

Group type: COMPARATOR
Intervention: Chemo-endocrine therapy
Number of subjects: 1113
Study: 19936714

Group type: EXPERIMENTAL
Intervention: d-amphetamine 20 mg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: d-amphetamine (0, 5, 10, and 20 mg)
Number of subjects: 99
Study: 17414392

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 1712
Study: 15502669

Group type: EXPERIMENTAL
Intervention: Intervention 1 plus $20 incentive paid at return visit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention 1 plus motivational counseling at the first visit and a phone reminder at 3 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention 1 plus phone reminder
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention 1 plus motivational counseling but no telephone reminder
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intervention 1
Number of subjects: 0
Study: 11335695

Group type: EXPERIMENTAL
Intervention: Consonant musical excerpts
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Dissonant musical excerpts
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Chord sequences with varying degrees of dissonance
Number of subjects: 1

Group type: COMPARATOR
Intervention: CT scan and PET activation data comparison
Number of subjects: 1
Study: 9556123

Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation (PC)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pressure-regulated volume-controlled ventilation (PRVC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Volume-controlled ventilation (VC)
Number of subjects: 10
Study: 7984694

Group type: EXPERIMENTAL
Intervention: Lisuride 1.0 mg daily dose
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 2500195

Group type: EXPERIMENTAL
Intervention: Isoflurane (0.1‐0.6% in air‐oxygen mixture)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Midazolam (continuous intravenous infusion of 0.01‐0.20 mg/kg/h)
Number of subjects: 60
Study: 31427860

Group type: EXPERIMENTAL
Intervention: Exercise (resistance exercise plus walking, 2 times weekly for 6 months)
Number of subjects: 30
Study: 25385719

Group type: EXPERIMENTAL
Intervention: High-volume online haemodiafiltration (HV-OL-HDF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard bicarbonate dialysis (BHD)
Number of subjects: 40
Study: 22340518

Group type: EXPERIMENTAL
Intervention: Pioglitazone (dose-escalation for three days followed by maintenance dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (placebo)
Number of subjects: 0
Study: 21223254

Group type: EXPERIMENTAL
Intervention: Dipyridamole added to aspirin
Number of subjects: 52